Viracta Therapeutics

Viracta is a precision oncology company targeting virus-associated malignancies. Viracta's proprietary investigational drug, nanatinostat, is currently being evaluated in combination with the antiviral agent valganciclovir as an oral combination therapy in a Phase 2 clinical trial for EBV-positive lymphoma. Viracta is pursuing application of this inducible synthetic lethality approach in other EBV-associated malignancies, such as nasopharyngeal carcinoma, gastric carcinoma, and other virus-related cancers.

Viracta Therapeutics headquartered in United States, North America, operates in the Biotechnology, Health Care, Pharmaceutical, Medical, Biopharma, Therapeutics, Oncology sector. The company focuses on Biotechnology and has secured $65.8B in funding across 280 round(s). With a team of 11-50 employees, Viracta Therapeutics is actively contributing to advancements in Biotechnology. Their latest funding round, Series B - Viracta Therapeutics, raised $12.0M. Discover more about their projects, partnerships, and impact on our platform.